Merck Patent Gmbh

Viventia Bio Inc.

Viventia Biotechnologies Inc.

National Research Council of Canada

Viventia Biotech Inc.

Francis J. Carr

Koen Hellendoorn

Nicholas Ronald Glover

Jeannick Cizeau

Joycelyn Entwistle

Glen Christopher Macdonald

Denis Georges Bosc

Matthew Baker

Francis Joseph Carr

Glen MacDonald

Francina C Chahal

Francis J Carr

Denis Bosc

Jamshid Tanha

Saran A Narang

Michael D Dan

Colin Roger Mackenzie

Arjune Premsukh

Howard Kaplan

Shilpa Chooniedass

Nicholas R Glover

The present disclosure is related to compositions of antibodies and immunoconjugates that potentially lack T-cell epitopes and elicit reduced immune response. The antibody may be an antibody fragment, such as Fab, Fab', F(ab&#x2032;)2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments, multimers, and any combination thereof. In a further embodiment, the antibody may bind to an antigen epithelial cell adhesion molecule (EpCAM). In another embodiment, an immunoconjugate may comprise an antibody attached to an effector molecule, wherein the effector molecule may be a radioisotope, an antineoplastic agent, an immunomodulator, a biological response modifier, lectin, a toxin, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof.

Anti-EPCAM antibodies and methods of use

The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.

Tumor specific antibody

The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.

Cytotoxins comprising modified bouganin toxin for the treatment of cancer

The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.

Cancer specific antibody and cell surface proteins

CD44E tumor specific antibody

Phage display libraries are taught in which the recombinant phage population displays a plurality of potential binding fragments having preferred characteristics of solubility and/or intermolecular interaction. Also taught are methods of biasing display libraries to produce variants which more closely approximate the preferred characteristics of the parental binding fragment.

[object Object]

Cancer associated glucose transporter 8 variant

Modified bouganin proteins, cytotoxins and methods and uses thereof

Growing community of inventors

Winnipeg, Canada

Joycelyn Entwistle